← 홈

Antibody

1,230개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,230개
AntibodystaleRegeneron PharmaceuticalsPhase 2

Fianlimab (Fianlimab)

Ovarian Cancer; Fallopian Tube Cancer · NSCLC

#NSCLC#Antibody#Phase2#항체#면역항체+5
임상시험 39상태 RECRUITING
AntibodySanofiPhase 3

Isatuximab SAR650984 (Isatuximab SAR650984)

Immune System Disorder · Plasma Cell Myeloma

#PlasmaCellMyeloma#Antibody#Phase3#항체#면역항체+4
효능 ORR 55.6%임상시험 39상태 ACTIVE
AntibodystaleGruppo Oncologico del Nord-OvestPhase 2

Botensilimab (Botensilimab)

Colorectal Cancer; Resectable Colorectal Carcinoma · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#항체#면역항체+3
임상시험 38상태 RECRUITING
AntibodystaleGlaxoSmithKlinesPhase 3

Tarlatamab (Tarlatamab)

Neoplasms · Extensive-Stage Small Cell Lung Cancer

#Extensive-StageSmallCellLungCanc#Antibody#Phase3#항체#면역항체+4
효능 ORR 57.1%임상시험 36상태 RECRUITING
AntibodystaleHoffmann-La RochePhase 2

Hu5F9-G4 (Magrolimab, Magrolimab (Hu5F9-G4))

Urothelial Carcinoma; Bladder Cancer · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Phase2#항체#면역항체+4
효능 ORR 81.3%임상시험 35상태 ACTIVE
AntibodyJazz Pharmaceuticalsderuxtecan, telisotuzumab v…Phase 2

Zanidatamab (ZW25, ZW25 (Zanidatamab))

HER2+/HR+ Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+5
효능 ORR 33%임상시험 33상태 ACTIVE
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, Ipilimumab plus nivolumab)

Melanoma; Non Small Cell Lung Cancer · Melanoma

#Melanoma#Antibody#Phase2#항체#면역항체+3
효능 ORR 77.8%임상시험 32상태 RECRUITING
AntibodystaleAnaveon AGVedotin ± Pe…Phase 2

KEYTRUDA® (ANV600 + pembrolizumab, ANV600 + pembrolizumab (KEYTRUDA®))

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase2#항체#면역항체+4
효능 ORR 71.4%임상시험 31상태 RECRUITING
AntibodystaleETOP IBCSG Partners Foundationderuxtecan (Arm 4), followe…Phase 3

durvalumab (Imfinzi, Adjuvant durvalumab)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase3#항체#면역항체+4
효능 ORR 45%임상시험 31상태 RECRUITING
AntibodyBiologicstaleKyverna TherapeuticssPhase 2

Anti-CD20 mAB (Anti-CD20 mAB)

Multiple Sclerosis, Primary Progressive; Multiple Sclerosis, Secondary Progressive · CD20

#CD20#Antibody#Phase2#항체#면역항체+5
효능 ORR 89%임상시험 31상태 RECRUITING
AntibodystaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab - 21 Day Cycle)

Endometrial Cancer · Endometrial Cancer

#EndometrialCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 46.4%임상시험 31상태 RECRUITING
AntibodystaleRocheVedotin in Relapsed/Refract…Phase 2

Glofitamab/Obinutuzumab (Glofitamab/Obinutuzumab)

Richter Syndrome · FRα

#FR#Antibody#Phase2#항체#면역항체+5
효능 ORR 35.3%임상시험 31상태 RECRUITING
AntibodystaleMerck Sharp & Dohme LLCADCsPhase 3

H1 receptor antagonist (H1 receptor antagonist)

Ovarian Cancer; Fallopian Tube Cancer · Lung Neoplasm Malignant

#LungNeoplasmMalignant#Antibody#Phase3#항체#면역항체+5
효능 ORR 6%임상시험 31상태 RECRUITING
AntibodystaleMerck Sharp & Dohme LLCPhase 3

H2 receptor antagonist (H2 receptor antagonist)

Ovarian Cancer; Fallopian Tube Cancer · Lung Neoplasm Malignant

#LungNeoplasmMalignant#Antibody#Phase3#항체#면역항체+4
임상시험 31상태 RECRUITING
AntibodystaleRochePhase 3

atezolizumab (Tecentriq, Tiragolumab and Atezolizumab)

Head and Neck Neoplasms; MSI-H Cancer · Cancer

#Cancer#Antibody#Phase3#항체#면역항체+5
효능 ORR 77.3%임상시험 31상태 RECRUITING
AntibodystaleRocheVedotin Plus an Anti-CD20 M…Phase 2

Zanubrutinib and Rituximab (Zanubrutinib and Rituximab)

Untreated Mantle Cell Lymphoma · Mantle Cell Lymphoma

#MantleCellLymphoma#Antibody#Phase2#항체#면역항체+5
효능 ORR 48.7%임상시험 31상태 RECRUITING
AntibodyQuantumLeap Healthcare Collabor…Phase 2

AMG 479 (AMG 479, Ganitumab, AMG 479 (Ganitumab) plus Metformin)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+5
효능 ORR 27%임상시험 30상태 RECRUITING
AntibodystaleRochevedotin and anti-CD19 chime…Phase 2

Acalabrutinib combination with Rituximab (Acalabrutinib combination with Rituximab)

Mantle-cell Lymphoma · Mantle-cell Lymphoma

#Mantle-cellLymphoma#Antibody#Phase2#항체#면역항체+4
효능 ORR 66.4%임상시험 30상태 RECRUITING
AntibodystaleTang-Du Hospitalvedotin (RC48) in combinati…Phase 2

Adebrelimab combined with Apatinib (Adebrelimab combined with Apatinib)

SCLC · SCLC

#SCLC#Antibody#Phase2#항체#면역항체+4
임상시험 30상태 RECRUITING
AntibodystaleNantes University HospitalPreclinical

Azathioprine + infliximab (Azathioprine + infliximab)

Crohn Disease · Crohn Disease

#CrohnDisease#Antibody#Preclinical#항체#면역항체+3
효능 ORR 6%임상시험 30상태 RECRUITING

7 / 62 페이지

← 이전다음 →